The 81,600 dose of the AstraZeneca vaccine will arrive Sunday morning at the National Medical-Military Development Research Institute “Contaguccino”. Transportation provided by the manufacturing company land arrived in Romania on Saturday.
The dosages will be stored at the National Storage Center, and in the near future they will be distributed nationwide at existing regional centers, sending the CNCAV’s Communications Team to the National Coordinating Committee for Vaccine Measures against COVID-19.
The National Center for the Storage of COVID-19 Vaccines Within “Kontakuccino” is fully accredited by the National Authority for Drugs and Medical Devices of Romania (ANMDMR) for its use as a competent national authority in the field of medical products for humans.
Following accreditation from ANMDMR, the National Institute for Medical-Military Development Research “Kontakucino” as a wholesale distributor may perform operations such as possession, detention and dispensing of drugs requiring additional criteria: with corresponding products art. 806 of Act 95/2006 relating to health reform, reprinted: Immunosuppressive drugs, products with cold chain distribution, respectively (requiring handling at lower temperatures).
On January 29, 2021, the European Pharmaceuticals Association recommended conditional marketing approval for a vaccine against COVID-19 developed by Astrogeneka.
EMA’s Panel on Human-Use Medicinal Products (CHMP) evaluated data on vaccine quality, safety and efficacy and unanimously recommended that the European Commission grant conditional marketing accreditation.
The Astrogeneca vaccine is the third vaccine against COVID-19, available for vaccination campaigns in EU member states and indirectly in Romania.
The European Pharmaceuticals Agency (EMA) agreed on January 29 to use the vaccine, produced by AstraZeneca, in EU countries over the age of 18.
E.M.A. He warned that there were not enough results for people over the age of 55 to calculate the effectiveness of the vaccine for these individuals.
“However, security is expected.” The immune response has been identified.
“EMA scientists estimate that the vaccine could be used in the elderly because it has reliable safety data for people over 55. More information is expected from current studies covering a higher proportion of older participants.”, Explained the European company.
It is the third EU-approved vaccine after Pfizer / Bioendech and Moderna.
Studies show that the vaccine is very effective in preventing acute coronavirus infection and death.
This vaccine also has the advantage of having a lower production cost than competing vaccines, while being easier to store and transport.
However, the elderly had concerns about its effectiveness, even in the absence of adequate data, as less than 10% of volunteers were over 65 years of age.
A few hours ago, European Commission President Ursula van der Leyen, in a dispute with a British-Swedish manufacturer, decided to reduce the amount of vaccines supplied to the EU and released a signed agreement with that company. It “Binding Rules and That is very clear. “
After announcing that it would supply fewer volumes to the EU due to production problems at the Belgian plant, it was suspected that the company would repatriate more volumes to the UK.
The 300 million dose in the August agreement is to be given after approval to the EU, and with the option of 100 million.
The EU scandal, linked by EU Health Commissioner Stella Kryakits, to the fact that the EU has pre-funded the development and production of the vaccine and linked it to “wanting to see an end”.
The Astrogeneca vaccine, developed in collaboration with the University of Oxford on the basis of an improved virus, has already been approved in the UK for several weeks and has already vaccinated millions of people.
There were also problems with the Pfizer / Bioentech vaccine.
Pfizer has announced that it will temporarily reduce its supply of anti-Govt vaccine to Europe to improve its productivity.
FHI says restricting Pfizer production will reduce deliveries, which could increase production capacity from its current 1.3 billion to 2 billion dose vaccines a year.
On the other hand, the company announced that it could deliver the U.S. vaccine dose much faster than previously expected.